The FDA approved ropinirole in September 1997.
Ropinirole clearance may be altered by coadministration of norfloxacin, an inhibitor of CYP1A2.
Keep REQUIP in a tightly closed container and out of direct sunlight. Oral treatment of pregnant rats with ropinirole during organogenesis resulted in decreased fetal body weight, increased fetal death, and digital malformations at 24, 36, and 60 times, respectively, the maximum recommended human dose MRHD for Parkinson s disease 24 mg day on a mg m basis.
Take REQUIP or REQUIP XL exactly as directed by your healthcare provider. You can ask your healthcare provider or pharmacist for information about REQUIP and REQUIP XL that is written for healthcare professionals. Ropinirole has no affinity at the D1-like receptors, benzodiazepine or GABA receptors 4. If augmentation or early-morning rebound occurs, the use of REQUIP should be reviewed and dosage adjustment or discontinuation of treatment should be considered.
Ask your doctor before use if you are taking the following medications:
Serious gastrointestinal adverse effects such as bleeding, ulceration and perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.
Monitor serum sodium more frequently in patients 65 years of age and older and in patients at increased risk of hyponatremia.
Your doctor may occasionally change your dose to make sure you get the best results. If you have reduced kidney function recommend kidney disease, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.
Back, muscle, or joint pain Pain, burning, numbness, or tingling in your hands or feet Swelling in your hands, arms, feet, ankles, or lower legs. To lower the chance of feeling dizzy or passing out, rise slowly if you have been sitting or lying down.